# Biomimetic sequentially gated nanotuners based on amorphous metal–organic frameworks for reprogramming the metabolism-ferroptosis-immunity crosstalk in gliomas

**Authors:** Bin Wang, Na Yin, Xinrui Liu, Yi Guan, Haiyang Xu, Ying Yu, Yang Bai, Yue Cao, Ziqian Wang, Shiqi Bai, Shaopeng Zhang, Donghao Qu, Wanying Li, Zhijia Lv, Yunqian Li, Hongquan Yu, Yinghui Wang

PMC · DOI: 10.1016/j.mtbio.2026.102973 · Materials Today Bio · 2026-02-26

## TL;DR

A new nanotuner (ZB@HM) reprograms glioma metabolism and immunity to enhance ferroptosis and antitumor immunity.

## Contribution

A biomimetic sequentially gated nanotuner that modulates metabolism-ferroptosis-immunity crosstalk in gliomas.

## Key findings

- ZB@HM triggers ferroptosis and immunogenic cell death via NADPH and cysteine depletion.
- Methionine restriction by ZB@HM suppresses tumor cysteine biosynthesis and enhances T-cell methionine uptake.
- Treatment with ZB@HM downregulates immune checkpoints and reverses T-cell exhaustion.

## Abstract

Glioma's metabolic reprogramming fortifies antioxidant defenses and fosters an immunosuppressive microenvironment, thus resulting in robust resistance to ferroptosis-immunotherapy. In this study, a biomimetic sequentially gated amorphous MOF-based nanotuner (ZB@HM) was constructed, which could cascade depletion of metabolic substrates of ferroptosis defense and redistribution of methionine for reprogramming metabolism-ferroptosis-immunity crosstalk. Specifically, we engineered a methionine-inhibitor-loaded amorphous ZIF-82, followed by coating with E. coli-glioma hybrid membrane to improve its blood-brain barrier penetration and gliomas-targeting. The amorphous MOF undergoes acidic-triggered disintegration, releasing 2-nitroimidazole that is selectively activated via NADPH reduction in hypoxia. The activated ligand subsequently covalently binds with thiol-containing cysteine. The cascade depletion of NADPH and cysteine, synergizing with Zn2+ overload, effectively triggers robust ferroptosis and immunogenic cell death. Moreover, ZB@HM selectively restricts methionine uptake in gliomas, suppressing the transsulfuration pathway for cysteine biosynthesis and enhancing the competitive uptake of methionine by T cells. The reduced intracellular methionine pool in gliomas diminishes S-adenosylmethionine biosynthesis, downregulating immune checkpoint expression. This cascade reverses T-cell exhaustion and reinforces antitumor immunity. RNA sequencing analysis revealed that treatment with ZB@HM resulted in a modulation of gene signatures associated with the GSH metabolism and tumor immunotherapy. Collectively, ZB@HM reprograms the metabolism-ferroptosis-immune crosstalk through orchestrating multiple key metabolites.

This study synthesizes a biomimetic sequentially gated (acidity-hypoxia responsive) MOF-based nanotuner (ZB@HM) that remodels immunosuppressive microenvironment by reprogramming metabolism-ferroptosis-immunity crosstalk network. Mechanistically, ZB@HM undergoes acid-mediated degradation, releasing 2-nitroimidazole, which disrupts ferroptosis defense via hypoxia-responsive NADPH/cysteine cascade depletion. Released methionine uptake inhibitors selectively restricts tumor's methionine supply, potentiating ferroptosis, downregulating immune checkpoints and reversing T-cell exhaustion.Image 1

## Linked entities

- **Chemicals:** 2-nitroimidazole (PubChem CID 10701), NADPH (PubChem CID 5884), cysteine (PubChem CID 594), S-adenosylmethionine (PubChem CID 34755), Zn2+ (PubChem CID 32051)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Txn1 (thioredoxin 1) [NCBI Gene 22166] {aka ADF, Trx1, Txn}, Calr (calreticulin) [NCBI Gene 12317] {aka CRT, Calregulin}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, H3c7 (H3 clustered histone 7) [NCBI Gene 260423] {aka H3.2-221, H3c13, H3c14, H3c15, H3c2, H3c3}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Slc7a11 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 11) [NCBI Gene 26570] {aka 9930009M05Rik, sut, xCT}, Cd80 (CD80 antigen) [NCBI Gene 12519] {aka B71, Cd28l, Ly-53, Ly53, MIC17, TSA1}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Cd8a (CD8 subunit alpha) [NCBI Gene 12525] {aka Ly-2, Ly-35, Ly-B, Lyt-2}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Hsp90b1 (heat shock protein 90, beta (Grp94), member 1) [NCBI Gene 22027] {aka ERp99, GRP94, TA-3, Targ2, Tra-1, Tra1}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, Cd247 (CD247 antigen) [NCBI Gene 12503] {aka 4930549J05Rik, A430104F18Rik, Cd3, Cd3-eta, Cd3-zeta, Cd3h}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Slc3a2 (solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2) [NCBI Gene 17254] {aka 4F2, 4F2HC, Cd98, Ly-10, Ly-m10, Ly10}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Slc7a5 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 5) [NCBI Gene 20539] {aka 4F2LC, D0H16S474E, Gm42049, LAT1, TA1}
- **Diseases:** Tumor (MESH:D009369), MOF (MESH:D013651), Glioma (MESH:D005910), Mitochondrial damage (MESH:D028361), hypoxia (MESH:D000860), hemolysis (MESH:D006461), hypoxic (MESH:D002534), nervous system tumors (MESH:D009423), T (MESH:D001260), cytotoxicity (MESH:D064420), ICD (MESH:D003643), dislocation (MESH:D004204), brain tumor (MESH:D001932), dysfunction (MESH:D006331)
- **Chemicals:** N2 (MESH:D009584), MOF (MESH:D000073396), FITC (MESH:D016650), 2-Nitroimidazole (MESH:C006667), polyacrylamide (MESH:C016679), nitroimidazole (MESH:D009593), paraffin (MESH:D010232), Calcein-AM (MESH:C085925), Methionine (MESH:D008715), metal (MESH:D008670), C11-BODIPY581/591 (MESH:C120421), Zinc (MESH:D015032), HCl (MESH:D006851), SDS (MESH:D012967), ethanol (MESH:D000431), Aqua (MESH:D014867), BCH (MESH:C076758), S-adenosylmethionine (MESH:D012436), 2',7-dichlorofluorescein diacetate (MESH:C029569), HM (MESH:C100283), NADP+ (MESH:D009249), thiol (MESH:D013438), fluorescein (MESH:D019793), MDA (MESH:D008315), H&amp;E (MESH:D006371), crystal violet (MESH:D005840), PI (MESH:D011419), 1H-Imidazole-4-carbonitrile (-), hematoxylin (MESH:D006416), MOF (MESH:C037042), JC-1 (MESH:C068624), hydrogen (MESH:D006859), Zinc nitrate hexahydrate (MESH:C042103), PVDF (MESH:C024865), eosin (MESH:D004801), ROS (MESH:D017382), HNO3 (MESH:D017942), DAPI (MESH:C007293), formalin (MESH:D005557), DAMPs (MESH:C116255), Rhodamine B (MESH:C029773), CO2 (MESH:D002245), GSH (MESH:D005978), ATP (MESH:D000255), N, N-Dimethylformamide (MESH:D004126), cysteine (MESH:D003545), lipid (MESH:D008055)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Escherichia coli K1 (strain) [taxon 1392869], Escherichia coli (E. coli, species) [taxon 562]
- **Cell lines:** GL261 — Mus musculus (Mouse), Mouse glioblastoma, Cancer cell line (CVCL_Y003), bEnd.3 — Mus musculus (Mouse), Transformed cell line (CVCL_0170), BV2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), ZIF-82 — Homo sapiens (Human), Xeroderma pigmentosum, complementation group A, Finite cell line (CVCL_L495)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12969143/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12969143/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12969143/full.md

---
Source: https://tomesphere.com/paper/PMC12969143